Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anti Infect Ther. 2007 Feb;5(1):13-28.

Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.

Author information

1
Division of Infectious Diseases, University of Toronto, Toronto, Canada. darrell.tan@gmail.com

Abstract

Lopinavir is a protease inhibitor (PI) for the treatment of HIV infection that was specifically designed to overcome the shortcomings of earlier agents in this class. It is the only PI coformulated with ritonavir, whose pharmacological boosting effect results in a highly potent, well-tolerated, clinically effective antiretroviral agent with a high genetic barrier to resistance. Lopinavir/ritonavir is a recommended first-line option for antiretroviral-naive patients initiating PI-based therapy, and has an equally important role in the management of treatment-experienced individuals. Its favorable pharmacological and clinical characteristics have recently prompted investigators to explore its potential novel applications in HIV monotherapy and double-boosted regimens.

PMID:
17266450
DOI:
10.1586/14787210.5.1.13
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center